+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Myeloproliferative Disorders Drugs Market Size, Share & Trends Analysis Report By Indication, By Treatment Type, By End Use, By Region, And Segment Forecasts, 2025 - 2030

  • PDF Icon

    Report

  • 100 Pages
  • December 2024
  • Region: Global
  • Grand View Research
  • ID: 6040823
Description Jump to:

Myeloproliferative Disorders Drugs Market Growth & Trends

The global myeloproliferative disorders drugs market size is expected to reach USD 15.83 billion by 2030, registering a CAGR of 5.9% from 2025 to 2030. Availability of novel drugs, the presence of a strong pipeline, rising incidence of myeloproliferative disorders due to changing lifestyles, growing geriatric population, and increasing public awareness are some of the primary growth stimulants for the market. Therapeutic development in the second-line setting for Jakafi-intolerant patients is estimated to work in favor of the Ph- MPNs market.

Chronic myeloproliferative disorders are rare hematological malignances that involve the abnormal accumulation of mature myeloid cells (red blood cells, granulocytes, and platelets) and their precursors (myelocytes, metamyelocytes, nucleated red blood cells, and megakaryocytes) in the peripheral blood and bone marrow. This class of disorder includes four main myeloproliferative diseases, which are further categorized by the presence of the Philadelphia chromosome.

There is a higher incidence of myeloproliferative disorders in North America and Western Europe as compared to East-Asian countries. Most patients are diagnosed with MPNs after 60 years of age, however, the diseases can occur in any age group. The U.S. will be the most prominent market for myeloproliferative disorders drugs owing to the presence of a large target population.

Myeloproliferative Disorders Drugs Market Report Highlights

  • North America myeloproliferative disorders drugs market dominated the global market with a revenue share of 40.2% in 2024, driven by high prevalence rates of myeloproliferative disorders coupled with advanced healthcare infrastructure that supports innovative treatments.
  • Strong unmet needs are likely to shape the future of the market and encourage the development of breakthrough first-in-class therapies. Opportunities remain in the Ph- MPNs setting where there exists an unmet need for a safer drug than Jakafi with higher cure rates and lesser allergic effects
  • Some of the key market participants are Novartis, Bristol-Myers Squibb, Pfizer, Takeda, Incyte, and Teva. Primary go-to strategies of prominent players include collaborations for the development and regional expansion in emerging markets.

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Indication
1.2.2. Treatment Type
1.2.3. End Use
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Myeloproliferative Disorders Drugs Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
Chapter 4. Myeloproliferative Disorders Drugs Market: Indication Business Analysis
4.1. Indication Market Share, 2024 & 2030
4.2. Indication Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Billion)
4.4. Ph+ Chronic Myelogenous Leukemia (CML)
4.4.1. Ph+ Chronic Myelogenous Leukemia (CML) Market, 2018 - 2030 (USD Billion)
4.5. Ph- Myeloproliferative Neoplasms (MPNs)
4.5.1. Ph- Myeloproliferative Neoplasms (MPNs) Market, 2018 - 2030 (USD Billion)
4.5.2. Myelofibrosis (MF)
4.5.3. Myelofibrosis (MF) Market, 2018 - 2030 (USD Billion)
4.5.4. Polycythemia Vera (PV)
4.5.5. Polycythemia Vera (PV) Market, 2018 - 2030 (USD Billion)
4.5.6. Essential Thrombocythemia (ET)
4.5.7. Essential Thrombocythemia (ET) Market, 2018 - 2030 (USD Billion)
Chapter 5. Myeloproliferative Disorders Drugs Market: Treatment Type Business Analysis
5.1. Treatment Type Market Share, 2024 & 2030
5.2. Treatment Type Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Treatment Type, 2018 to 2030 (USD Billion)
5.4. Chemotherapy
5.4.1. Chemotherapy Market, 2018 - 2030 (USD Billion)
5.5. Targeted Therapy
5.5.1. Targeted Therapy Market, 2018 - 2030 (USD Billion)
5.6. Others
5.6.1. Others Market, 2018 - 2030 (USD Billion)
Chapter 6. Myeloproliferative Disorders Drugs Market: End Use Business Analysis
6.1. End Use Market Share, 2024 & 2030
6.2. End Use Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Billion)
6.4. Hospitals
6.4.1. Hospitals Market, 2018 - 2030 (USD Billion)
6.5. Specialty Clinics
6.5.1. Specialty Clinics Market, 2018 - 2030 (USD Billion)
6.6. Others
6.6.1. Others Market, 2018 - 2030 (USD Billion)
Chapter 7. Myeloproliferative Disorders Drugs Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
7.4. North America
7.4.1. North America Myeloproliferative Disorders Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Regulatory Framework
7.4.2.3. Competitive Insights
7.4.2.4. U.S. Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Regulatory Framework
7.4.3.3. Competitive Insights
7.4.3.4. Canada Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.4.4. Mexico
7.4.4.1. Key Country Dynamics
7.4.4.2. Regulatory Framework
7.4.4.3. Competitive Insights
7.4.4.4. Mexico Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5. Europe
7.5.1. Europe Myeloproliferative Disorders Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
7.5.2. UK
7.5.2.1. Key Country Dynamics
7.5.2.2. Regulatory Framework
7.5.2.3. Competitive Insights
7.5.2.4. UK Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.3. Germany
7.5.3.1. Key Country Dynamics
7.5.3.2. Regulatory Framework
7.5.3.3. Competitive Insights
7.5.3.4. Germany Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.4. France
7.5.4.1. Key Country Dynamics
7.5.4.2. Regulatory Framework
7.5.4.3. Competitive Insights
7.5.4.4. France Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.5. Italy
7.5.5.1. Key Country Dynamics
7.5.5.2. Regulatory Framework
7.5.5.3. Competitive Insights
7.5.5.4. Italy Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.6. Spain
7.5.6.1. Key Country Dynamics
7.5.6.2. Regulatory Framework
7.5.6.3. Competitive Insights
7.5.6.4. Spain Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.7. Norway
7.5.7.1. Key Country Dynamics
7.5.7.2. Regulatory Framework
7.5.7.3. Competitive Insights
7.5.7.4. Norway Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.8. Denmark
7.5.8.1. Key Country Dynamics
7.5.8.2. Regulatory Framework
7.5.8.3. Competitive Insights
7.5.8.4. Denmark Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5.9. Sweden
7.5.9.1. Key Country Dynamics
7.5.9.2. Regulatory Framework
7.5.9.3. Competitive Insights
7.5.9.4. Sweden Myeloproliferative Disorders Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
7.6. Asia Pacific
7.6.1. Asia Pacific Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.6.2. Japan
7.6.2.1. Key Country Dynamics
7.6.2.2. Regulatory Framework
7.6.2.3. Competitive Insights
7.6.2.4. Japan Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.6.3. China
7.6.3.1. Key Country Dynamics
7.6.3.2. Regulatory Framework
7.6.3.3. Competitive Insights
7.6.3.4. China Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.6.4. India
7.6.4.1. Key Country Dynamics
7.6.4.2. Regulatory Framework
7.6.4.3. Competitive Insights
7.6.4.4. India Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.6.5. South Korea
7.6.5.1. Key Country Dynamics
7.6.5.2. Regulatory Framework
7.6.5.3. Competitive Insights
7.6.5.4. South Korea Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.6.6. Australia
7.6.6.1. Key Country Dynamics
7.6.6.2. Regulatory Framework
7.6.6.3. Competitive Insights
7.6.6.4. Australia Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.6.7. Thailand
7.6.7.1. Key Country Dynamics
7.6.7.2. Regulatory Framework
7.6.7.3. Competitive Insights
7.6.7.4. Thailand Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.7. Latin America
7.7.1. Latin America Myeloproliferative Disorders Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Regulatory Framework
7.7.2.3. Competitive Insights
7.7.2.4. Brazil Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Regulatory Framework
7.7.3.3. Competitive Insights
7.7.3.4. Argentina Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.8. MEA
7.8.1. MEA Myeloproliferative Disorders Drugs Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
7.8.2. South Africa
7.8.2.1. Key Country Dynamics
7.8.2.2. Regulatory Framework
7.8.2.3. Competitive Insights
7.8.2.4. South Africa Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.8.3. Saudi Arabia
7.8.3.1. Key Country Dynamics
7.8.3.2. Regulatory Framework
7.8.3.3. Competitive Insights
7.8.3.4. Saudi Arabia Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.8.4. UAE
7.8.4.1. Key Country Dynamics
7.8.4.2. Regulatory Framework
7.8.4.3. Competitive Insights
7.8.4.4. UAE Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.8.5. Kuwait
7.8.5.1. Key Country Dynamics
7.8.5.2. Regulatory Framework
7.8.5.3. Competitive Insights
7.8.5.4. Kuwait Myeloproliferative Disorders Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
Chapter 8. Competitive Landscape
8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
8.5.1. Novartis AG
8.5.1.1. Overview
8.5.1.2. Financial Performance
8.5.1.3. Product Benchmarking
8.5.1.4. Strategic Initiatives
8.5.2. Bristol-Myers Squibb Company
8.5.2.1. Overview
8.5.2.2. Financial Performance
8.5.2.3. Product Benchmarking
8.5.2.4. Strategic Initiatives
8.5.3. Pfizer Inc.
8.5.3.1. Overview
8.5.3.2. Financial Performance
8.5.3.3. Product Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. Takeda Pharmaceutical Company Limited.
8.5.4.1. Overview
8.5.4.2. Financial Performance
8.5.4.3. Product Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. Incyte.
8.5.5.1. Overview
8.5.5.2. Financial Performance
8.5.5.3. Product Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. Teva Pharmaceutical Industries Ltd.
8.5.6.1. Overview
8.5.6.2. Financial Performance
8.5.6.3. Product Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. AbbVie Inc.
8.5.7.1. Overview
8.5.7.2. Financial Performance
8.5.7.3. Product Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. Eli Lilly and Company.
8.5.8.1. Overview
8.5.8.2. Financial Performance
8.5.8.3. Product Benchmarking
8.5.8.4. Strategic Initiatives
8.5.9. GSK plc.
8.5.9.1. Overview
8.5.9.2. Financial Performance
8.5.9.3. Product Benchmarking
8.5.9.4. Strategic Initiatives
8.5.10. GL Pharma
8.5.10.1. Overview
8.5.10.2. Financial Performance
8.5.10.3. Product Benchmarking
8.5.10.4. Strategic Initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global myeloproliferative disorders drugs market, by region, 2018 - 2030 (USD Billion)
Table 4 Global myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
Table 5 Global myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
Table 6 Global myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
Table 7 North America myeloproliferative disorders drugs market, by country, 2018 - 2030 (USD Billion)
Table 8 North America myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
Table 9 North America myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
Table 10 North America myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
Table 11 U.S. myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
Table 12 U.S. myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
Table 13 U.S. myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
Table 14 Canada myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
Table 15 Canada myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
Table 16 Canada myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
Table 17 Mexico myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
Table 18 Mexico myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
Table 19 Mexico myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
Table 20 Europe myeloproliferative disorders drugs market, by country, 2018 - 2030 (USD Billion)
Table 21 Europe myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
Table 22 Europe myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
Table 23 Europe myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
Table 24 UK myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
Table 25 UK myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
Table 26 UK myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
Table 27 Germany myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
Table 28 Germany myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
Table 29 Germany myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
Table 30 France myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
Table 31 France myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
Table 32 France myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
Table 33 Italy myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
Table 34 Italy myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
Table 35 Italy myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
Table 36 Spain myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
Table 37 Spain myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
Table 38 Spain myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
Table 39 Norway myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
Table 40 Norway myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
Table 41 Norway myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
Table 42 Denmark myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
Table 43 Denmark myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
Table 44 Denmark myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
Table 45 Sweden myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
Table 46 Sweden myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
Table 47 Sweden myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
Table 48 Asia Pacific myeloproliferative disorders drugs market, by country, 2018 - 2030 (USD Billion)
Table 49 Asia Pacific myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
Table 50 Asia Pacific myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
Table 51 Asia Pacific myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
Table 52 Japan myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
Table 53 Japan myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
Table 54 Japan myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
Table 55 China myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
Table 56 China myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
Table 57 China myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
Table 58 India myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
Table 59 India myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
Table 60 India myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
Table 61 Australia myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
Table 62 Australia myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
Table 63 Australia myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
Table 64 South Korea myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
Table 65 South Korea myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
Table 66 South Korea myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
Table 67 Thailand myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
Table 68 Thailand myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
Table 69 Thailand myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
Table 70 Latin America myeloproliferative disorders drugs market, by country, 2018 - 2030 (USD Billion)
Table 71 Latin America myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
Table 72 Latin America myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion
Table 73 Latin America myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion
Table 74 Brazil myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
Table 75 Brazil myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
Table 76 Brazil myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
Table 77 Argentina myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
Table 78 Argentina myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
Table 79 Argentina myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
Table 80 Middle East & Africa myeloproliferative disorders drugs market, by country, 2018 - 2030 (USD Billion)
Table 81 Middle East & Africa myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
Table 82 Middle East & Africa myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
Table 83 Middle East & Africa myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
Table 84 South Africa myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
Table 85 South Africa myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
Table 86 South Africa myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
Table 87 Saudi Arabia myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
Table 88 Saudi Arabia myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
Table 89 Saudi Arabia myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
Table 90 UAE myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
Table 91 UAE myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
Table 92 UAE myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
Table 93 Kuwait myeloproliferative disorders drugs market, by indication, 2018 - 2030 (USD Billion)
Table 94 Kuwait myeloproliferative disorders drugs market, by treatment type, 2018 - 2030 (USD Billion)
Table 95 Kuwait myeloproliferative disorders drugs market, by end use, 2018 - 2030 (USD Billion)
List of Figures
Fig. 1 Myeloproliferative disorders drugs market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Indication outlook (USD Billion)
Fig. 10 Treatment type outlook (USD Billion)
Fig. 11 End use outlook (USD Billion)
Fig. 12 Competitive landscape
Fig. 13 Myeloproliferative disorders drugs market dynamics
Fig. 14 Myeloproliferative disorders drugs market: Porter’s five forces analysis
Fig. 15 Myeloproliferative disorders drugs market: PESTLE analysis
Fig. 16 Myeloproliferative disorders drugs market: Indication segment dashboard
Fig. 17 Myeloproliferative disorders drugs market: Indication market share analysis, 2024 & 2030
Fig. 18 Ph+ Chronic myelogenous leukemia (CML) market, 2018 - 2030 (USD Billion)
Fig. 19 Ph- Myeloproliferative neoplasms (MPNs) market, 2018 - 2030 (USD Billion)
Fig. 20 Myelofibrosis (MF) market, 2018 - 2030 (USD Billion)
Fig. 21 Polycythemia vera (PV) market, 2018 - 2030 (USD Billion)
Fig. 22 Essential thrombocythemia (ET) market, 2018 - 2030 (USD Billion)
Fig. 23 Myeloproliferative disorders drugs market: Treatment type segment dashboard
Fig. 24 Myeloproliferative disorders drugs market: Treatment type market share analysis, 2024 & 2030
Fig. 25 Chemotherapy market, 2018 - 2030 (USD Billion)
Fig. 26 Targeted therapy market, 2018 - 2030 (USD Billion)
Fig. 27 Others market, 2018 - 2030 (USD Billion)
Fig. 28 Myeloproliferative disorders drugs market: End use segment dashboard
Fig. 29 Myeloproliferative disorders drugs market: End use market share analysis, 2024 & 2030
Fig. 30 Hospitals market, 2018 - 2030 (USD Billion)
Fig. 31 Specialty clinics market, 2018 - 2030 (USD Billion)
Fig. 32 Others market, 2018 - 2030 (USD Billion)
Fig. 33 Myeloproliferative disorders drugs market revenue, by region
Fig. 34 Regional marketplace: Key takeaways
Fig. 35 North America myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
Fig. 36 U.S. country dynamics
Fig. 37 U.S. myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
Fig. 38 Canada country dynamics
Fig. 39 Canada myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
Fig. 40 Mexico country dynamics
Fig. 41 Mexico myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
Fig. 42 Europe myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
Fig. 43 UK country dynamics
Fig. 44 UK myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
Fig. 45 Germany country dynamics
Fig. 46 Germany myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
Fig. 47 France country dynamics
Fig. 48 France myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
Fig. 49 Italy country dynamics
Fig. 50 Italy myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
Fig. 51 Spain country dynamics
Fig. 52 Spain myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
Fig. 53 Norway country dynamics
Fig. 54 Norway myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
Fig. 55 Denmark country dynamics
Fig. 56 Denmark myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion
Fig. 57 Sweden country dynamics
Fig. 58 Sweden myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
Fig. 59 Asia Pacific myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
Fig. 60 Japan country dynamics
Fig. 61 Japan myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
Fig. 62 China country dynamics
Fig. 63 China myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
Fig. 64 India country dynamics
Fig. 65 India myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
Fig. 66 South Korea country dynamics
Fig. 67 South Korea myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
Fig. 68 Australia country dynamics
Fig. 69 Australia myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
Fig. 70 Thailand country dynamics
Fig. 71 Thailand myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
Fig. 72 Latin America myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
Fig. 73 Brazil country dynamics
Fig. 74 Brazil myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
Fig. 75 Argentina country dynamics
Fig. 76 Argentina myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
Fig. 77 MEA myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
Fig. 78 South Africa country dynamics
Fig. 79 South Africa myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
Fig. 80 Saudi Arabia country dynamics
Fig. 81 Saudi Arabia myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
Fig. 82 UAE country dynamics
Fig. 83 UAE myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
Fig. 84 Kuwait country dynamics
Fig. 85 Kuwait myeloproliferative disorders drugs market, 2018 - 2030 (USD Billion)
Fig. 86 Company categorization
Fig. 87 Company market position analysis
Fig. 88 Strategic framework

Companies Mentioned

  • Novartis AG
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited.
  • Incyte.
  • Teva Pharmaceutical Industries Ltd.
  • AbbVie Inc.
  • Eli Lilly and Company.
  • GSK plc.
  • GL Pharma

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages100
PublishedDecember 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 11.34 billion
Forecasted Market Value ( USD ) by 2030 $ 15.83 billion
Compound Annual Growth Rate5.9%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Myeloproliferative Disorders Drugs - Global Strategic Business Report - Product Image

Myeloproliferative Disorders Drugs - Global Strategic Business Report

  • Report
  • 89 Pages
  • Global
From
Myeloproliferative Disorders Drugs Global Market Report 2024 - Product Image

Myeloproliferative Disorders Drugs Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Myeloproliferative Disorder Drug Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Myeloproliferative Disorder Drug Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 83 Pages
  • Global
From
Myeloproliferative Disorders Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Myeloproliferative Disorders Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 190 Pages
  • Global
From
Japan Myeloproliferative Disorders (MPD) Therapeutics Market, By Region, Competition, Forecast & Opportunities, 2020-2030F - Product Image

Japan Myeloproliferative Disorders (MPD) Therapeutics Market, By Region, Competition, Forecast & Opportunities, 2020-2030F

  • Report
  • 82 Pages
  • Japan
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.